

Liquid Biopsy with Emphasis on NIPT: Global Markets to 2023

<https://marketpublishers.com/r/LC0C996EC47EN.html>

Date: April 2019

Pages: 359

Price: US\$ 2,750.00 (Single User License)

ID: LC0C996EC47EN

Abstracts

REPORT SCOPE:

The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, NIPT methods, patents for both liquid biopsy and NIPT, and company profiles. The market sizes for liquid biopsy diagnostics with emphasis on NIPT are given for the years 2017, 2018 (estimated) and 2023 (forecasted).

This report reviews liquid biopsy biomarkers and technologies and provides background on why liquid biopsy is increasingly viewed as a replacement for, or a companion to, tissue biopsy. It then discusses several of the significant large-scale research initiatives that are contributing to liquid biopsy development. Market-driving forces are also discussed.

In addition to this, the report examines the markets by NIPT methods, high-risk and low-risk pregnancies and geography. The end-user segment of this market is based on disease area and healthcare setting. Disease areas include trisomy 21, 18 and 13 and Turner syndrome (a sex chromosome aneuploidy). Healthcare settings include diagnostic laboratories and hospitals. Market dynamics such as drivers and restraints for the NIPT market are also discussed.

The structure of several important industry subsectors was reviewed. The industry subsectors that are analyzed include next-generation sequencing (NGS) instruments, droplet digital PCR, target enrichment and amplification, single-cell DNA polymerase, prenatal screening, liquid biopsy, direct to consumer, and clinical laboratory.

The market for liquid biopsy diagnostics is analyzed by application (cancer, reproductive health, transplant), biomarker type (nucleic acids, cells, extracellular vesicles, proteins), analysis platform (microarray, NGS, PCR, proteomics and others), analysis purpose (screening/early detection, diagnosis, therapy guidance, monitoring) and geography (North America, Europe, Asia-Pacific, Rest of World). Similarly, the market size of non-cancer applications of liquid biopsy, NIPT, is analyzed based on risk-type, analysis purpose, biomarker class, analysis method, NIPT methods, high%li%and low-risk pregnancies, and geography.

Market data cover the years 2017, 2018 (estimated) and 2023 (forecasted).

More than 165 companies in the liquid biopsy industry are profiled in this report. Nearly 18 companies in the NIPT market have been profiled in detail.

BCC Research provides a summary of the main industry acquisitions and strategic alliances from January 2016 until December 2018, including key alliance trends.

REPORT INCLUDES:

45 data tables and 94 additional tables

An overview of liquid biopsy and non-invasive prenatal tests (NIPT) market

Analyses of global market trends with data from 2017, 2018 and projections of compound annual growth rates (CAGRs) through 2023

Country specific data and analysis for China, Japan, India, South Korea, UK, Germany, France, Italy, Spain and USA

Comparative study of liquid biopsy with conventional biopsy and coverage of their respective biomarkers

Snapshot of key liquid biopsy research and development programs

Information on NIPT available in market such as NIFTY, Verifi prenatal test, Harmony prenatal test, Panorama, MaterniT21 and IONA test

Description of chromosomal diseases where NIPT plays a vital role in detection and screening i.e. Down's Syndrome, Edwards Syndrome (Trisomy 18), Patau

syndrome (Trisomy 13) and Turner syndrome

Comprehensive company profiles of major players, including Agilent Technologies, Illumina, Natera, Oxford Nanopore, QIAGEN, and Thermo Fisher

Contents

CHAPTER 1 INTRODUCTION

Study Goals and Objectives
Reasons for Doing This Study
Scope of the Report
Information Sources
Methodology
Geographic Breakdown
Analyst's Credentials
BCC Custom Research
Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

CHAPTER 3 MARKET AND TECHNOLOGY BACKGROUND

Liquid Biopsy Overview
Liquid Biopsy versus Traditional Biopsy
Liquid Biopsy Biomarkers
Cancer Genomics
Noninvasive Prenatal Testing
Circulating Tumor Cell Technologies
CTC Workflow
Cell Isolation Technologies
CTC Sample Preparation Technologies
CTC Downstream Analysis Technologies
Comparison of Liquid Biopsy with Conventional Biopsy
Cancer Testing
Prenatal Testing
Growth Driving Forces
Key Trends
Key Developments in Liquid Biopsy

CHAPTER 4 LIQUID BIOPSY INITIATIVES

Blood Profiling Atlas
Cambridge Single Cell Analysis Core Facility

Cancer-ID
CTCTrap Consortium
Early Cancer Detection Consortium
Hematologic Oncology Consortium
National Center for Single-Cell Biology
Precancer Genome Atlas
Precision Medicine Initiative
Single Cell Analysis Program
TopMed
Worldwide Innovative Networking (WIN) Consortium
NIPT for Cancer Detection
Research Studies on NIPT for Cancer Detection

CHAPTER 5 LIQUID BIOPSY APPLICATIONS

Introduction
Cancer Applications
Precision Medicine
Cancer Biomarker Status
Cancer Market Segments
Reproductive Health Applications
Transplant Diagnostics Applications

CHAPTER 6 LIQUID BIOPSY SUBINDUSTRIES

Introduction
Advanced Sequencing Instruments Industry
NGS Instrument Industry
MiSeq
NextSeq
MiniSeq
ISeq
Ion Torrent
PromethION
MinION
GridION X5
Third-Generation Sequencing Industry
Droplet Digital PCR Industry
Target Enrichment and Amplification Industry

Single-Cell DNA Polymerase Industry
NGS Clinical Informatics Industry
Testing Services Industry
Noninvasive Prenatal Testing Industry
Fetal Cell NIPT Industry
CTC Capture and Detection Industry
Liquid Biopsy Industry
Direct-to-Consumer Genetic Testing Industry

CHAPTER 7 LIQUID BIOPSY INDUSTRY

Growth Driving Forces
Liquid Biopsy Market by Application
Liquid Biopsy Market by Biomarker Type
Liquid Biopsy Market by Analysis Platform
Liquid Biopsy Market by Analysis Purpose
Geographical Market

CHAPTER 8 MARKET BREAKDOWN BY INDICATION—CANCER AND TRANSPLANT

Cancer Markets
Cancer Market by Indication
Cancer Market by Analysis Purpose
Cancer Market by Biomarker Class
Cancer Market by Analysis Method
Breast Cancer Market
Colorectal Cancer Market
Hematological Cancer Market
Lung Cancer Market
Pan-Cancer Market
Geographical Market
Transplant Markets
Geographical Market

CHAPTER 9 NIPT INDUSTRY

NIPT—Introduction and Technology Overview
Other Conventional Prenatal Testing Methods

Advantages of NIPT
Positive Predictive Value
Implementation of NIPT Process
In-house Testing
As a Service
Factors Driving NIPT Market
Average Risk NIPT
Favorable Reimbursement
New Advances in Genomic Technologies
Preference for Noninvasive Techniques over Invasive Methods
Patient Counseling and Awareness
Increasing Collaborations with Local Entities
Increasing Mean Maternal Age
Restrains
Legal and Regulatory Issues
Access to Advancing Technologies
Current Market Scenario
Cost of NIPT
NGS-Based NIPT
NGS Sequencers for NIPT
VeriSeq NIPT Solution
MiSeqDx
NextSeq 550x
NextSeq 550AR
Noninvasive Prenatal Tests Available in Market
NIFTY
Verifi Prenatal Test
Harmony Prenatal Test
Panorama
MaterniT21
IONA Test
Iona Test Workflow
Bambni Test
informaSeq
Prena Test
VisibiliT
VERACITY
Geographical Market
North America

Europe
Asia-Pacific
Rest of the World

CHAPTER 10 LIQUID BIOPSY-NIPT END USERS

By Disease Area
Down Syndrome (Trisomy 21)
Edwards Syndrome (Trisomy 18)
Patau Syndrome (Trisomy 13)
Turner Syndrome
Others
By Healthcare Setting
Diagnostic Laboratories
Hospitals

CHAPTER 11 PATENT REVIEW/ NEW DEVELOPMENTS

Patent Review by Year
Circulating Tumor Cell Patents
Cell-Free DNA Patents
Liquid Biopsy- and Sequencing-Related Patent Issues

CHAPTER 12 ANALYSIS OF MARKET OPPORTUNITIES

Market Share Analysis
PEST Analysis
Political
Economical
Social
Technological

CHAPTER 13 COMPETITIVE LANDSCAPE

Mergers and Acquisitions
New Product Launches
Agreements, Collaborations and Partnerships
Pipeline Analysis

CHAPTER 14 COMPANY PROFILES

Key Players in NIPT Industry

10X GENOMICS

AGILENT TECHNOLOGIES INC.

BERRY GENOMICS

BGI (BEIJING GENOMICS INSTITUTE)

EUROFINS GATC BIOTECH

EUROFINS GATC—LIFECODEXX AG

ILLUMINA INC.

KNOME INC./TUTE GENOMICS/PIERIAN DX

LABCORP

LABCORP—SEQUENOM LABORATORIES

NATERA INC.

NIPD GENETICS

OXFORD NANOPORE TECHNOLOGIES LTD.

PACIFIC BIOSCIENCES OF CALIFORNIA

PIERIANDX INC.

PERKINELMER INC.

QIAGEN N.V.

ROCHE HOLDING AG

THERMO FISHER SCIENTIFIC INC.

Players in the Liquid Biopsy Industry

3D SIGNATURES

ADAPTIVE BIOTECHNOLOGIES INC.

ALCEDIAG

AMBRY GENETICS

ANGLE PLC

APOCELL INC.

ARUP LABORATORIES

ASURAGEN INC.

ATRECA INC.

AVIVA BIOSCIENCES

BAYLOR MIRACA GENETICS LABORATORIES INC.

BECTON, DICKINSON AND CO.

BELLWETHER BIO INC.

BIOCARTIS NV

BIOCEPT INC.

BIODESIX INC.

BIOFLUIDICA INC.
BIOGAZELLE
BIOMARX INC.
BIO-RAD LABORATORIES INC.
BIO-TECHNE LTD.
BIOVENDOR–LABORATORNI MEDICINA A.S.
BOREAL GENOMICS
CANCER GENETICS
CEGAT GMBH
CELLMAX LIFE
CELL MICROSYSTEMS INC.
CELSEE DIAGNOSTICS
CHRONIX BIOMEDICAL
CIRCULOGENE THERANOSTICS
CIRCULOMICS INC.
CLINOMICS CO. LTD.
CODIAK BIOSCIENCES
COLOR GENOMICS
COOPERSURGICAL INC.
CORIELL LIFE SCIENCES INC.
CYNVENIO BIOSYSTEMS INC.
CYTOTRACK APS
DANAHER CORP. /HACH CO.
DIACARTA INC.
DIAGNOLOGIX LLC
DIAGNOMICS
DIPLOID
DNA ELECTRONICS LTD.
DNALYTICS
DNANEXUS INC.
EDICO GENOME
ENVISION GENOMICS
EPIC SCIENCES
EXACT SCIENCES CORP.
EXOSOME DIAGNOSTICS INC.
FABRIC GENOMICS INC.
FLUXION BIOSCIENCES INC.
FOUNDATION MEDICINE INC.
FREENOME INC.

GENAPSYS INC.
GENEDX INC.
GENOMATIX SOFTWARE GMBH
GENOMIC HEALTH INC.
GENOMONCOLOGY
GENOSPACE
GIGAGEN INC.
GOOD START GENETICS INC.
GOLDEN HELIX
GRAIL
GUARDANT HEALTH INC.
HELITEC
HELIX OPCO LLC
HTG MOLECULAR DIAGNOSTICS INC.
HUMAN LONGEVITY INC.
INEX INNOVATIONS EXCHANGE PTE LTD.
INIVATA LTD.
INTERPACE DIAGNOSTICS LLC
INVITAE
INVIVOSCRIBE INC.
IREPERTOIRE INC.
KELLBENX INC.
LABORATORY CORP. OF AMERICA INC.
MDNA LIFE SCIENCES INC.
MDX HEALTH INC.
MEDGENOME LABS PVT. LTD.
MENARINI SILICON BIOSYSTEMS
MERCK KGAA
MOLECULAR HEALTH GMBH
MYRIAD GENETICS INC.
NAMOCCELL INC.
NANOSTRING TECHNOLOGIES INC.
NEOGENOMICS INC.
NEW ENGLAND BIOLABS
NEW ONCOLOGY GMBH
N-OF-ONE INC.
NOVOGENE CORP.
NUGEN TECHNOLOGIES INC.
NX PRENATAL INC.

ONCOCYTE CORP.
ONCODNA SA
PANGAEA ONCOLOGY
PARADIGM DIAGNOSTICS INC.
PARSEQ LAB S.R.O.
PATHWAY GENOMICS CORP.
PERSONAL GENOME DIAGNOSTICS INC.
PORTABLE GENOMICS LLC
PREDICINE INC.
PRENETICS
PROVISTA DIAGNOSTICS INC.
QUANTAPORE INC.
QUANTUM BIOSYSTEMS INC.
QUANTUMDX
QUEST DIAGNOSTICS INC.
RARECELLS SAS
RARECYTE INC.
REAL TIME GENOMICS INC.
RESOLUTION BIOSCIENCE INC.
SCREENCELL
SENGENICS INTERNATIONAL PTE LTD.
SEQUENCING.COM
SEVEN BRIDGES GENOMICS INC.
SINGLERA GENOMICS
SOPHIA GENETICS
SPERA MEDICAL
SPHERE FLUIDICS LTD.
STATION X INC.
STILLA TECHNOLOGIES
STRAND LIFE SCIENCES PVT. LTD.
STRATEC BIOMEDICAL AG
STRATOS GENOMICS INC.
SYAPSE
SYGNIS AG
SYSMEX INOSTICS GMBH
TAI DIAGNOSTICS INC.
TAKARA BIO INC.
THORNE DIAGNOSTICS INC.
TROVAGENE INC.

TRANSGENOMIC INC.
TWINSTRAND BIOSCIENCES
TWO PORE GUYS INC.
UBIQUITY GENOMICS INC.
VELA DIAGNOSTICS
VOLITIONRX
XCELL BIOSCIENCES INC.
YIKON GENOMICS CO. LTD.
YOURGENE HEALTH PLC
ZS GENETICS INC.

List Of Tables

LIST OF TABLES

Summary Table: Global Liquid Biopsy Market, by Disease Class, Through 2023

Table 1: Liquid Biopsy Sample Types

Table 2: Liquid Biopsy Biomarker Classes

Table 3: Clinical Implications of CTCs

Table 4: Key Applications of Circulating Tumor DNA (ctDNA)

Table 5: Comparison between Applications of ctDNA, CTCs and Exosomes

Table 6: Single-Cell Analysis to Identify Cancer Driver Mutations

Table 7: Genomics-Based Oncology Workflow

Table 8: Unique Challenges of CTC Capture and Analysis

Table 9: CTC Workflow

Table 10: Cell Differentiators

Table 11: Cell Isolation Technologies

Table 12: CTC-Isolating Markers

Table 13: CTC Sample Preparation Technologies

Table 14: Single-Cell Analysis Technologies

Table 15: Difference between Liquid Biopsy and Traditional Biopsy

Table 16: Estimated Annual Solid Biopsy Procedures Performed in the U.S. for Selected Cancers

Table 17: Main Risks for Needle-Based Tissue Biopsies

Table 18: Factors in Tissue Biopsy

Table 19: Prenatal Invasive Testing Technologies

Table 20: Invasive versus Noninvasive Prenatal Technologies

Table 21: Growth Driving Forces

Table 22: Key Trends in Liquid Biopsy Market

Table 23: Key Liquid Biopsy Research and Development Programs

Table 24: Source of Foreign Biomarkers for Liquid Biopsy Applications

Table 25: Personalized Medicine Driven by Cancer Common Genetic Mutations

Table 26: Cancer Liquid Biopsy Biomarker Clinical Status

Table 27: Cancer Liquid Biopsy Market Segments

Table 28: Reproductive Health Screening Application

Table 29: Ethical Issues Associated with NIPT

Table 30: Transplant Diagnostics Application

Table 31: Key Segments within the Liquid Biopsy Industry

Table 32: Advanced Sequencing Industry Company Positioning

Table 33: End-to-End Sequencing Approaches

Table 34: Next-Generation Sequencing Instrument Companies

Table 35: NGS Instruments

Table 36: Benchtop and Handheld Sequencer Platforms

Table 37: 3GS Industry, by Tier Status

Table 38: Advantages of Droplet Digital PCR for Single-Cell Analysis

Table 39: Droplet Digital PCR Industry

Table 40: Target Enrichment Industry

Table 41: Single-Cell DNA Polymerase Industry

Table 42: Next-Generation Sequencing Clinical Informatics Company Positioning

Table 43: Selected NGS Clinical Testing Laboratories

Table 44: NIPT Industry

Table 45: Estimated Market Share for NIPT, 2018

Table 46: German NGS-Based Noninvasive Prenatal Diagnostic Companies, 2017

Table 47: NIPT Test Licensing, by Country

Table 48: Fetal Cell NIPT Industry

Table 49: CTC Capture and Detection Industry

Table 50: Liquid Biopsy Industry by Company Focus

Table 51: Example of NGS-Based Liquid Biopsy Market Differentiation

Table 52: Key Competitors in the Direct-to-Consumer Genetic Testing Industry

Table 53: Liquid Biopsy Key Growth Driving Forces

Table 54: Global Liquid Biopsy Market, by Application, Through 2023

Table 55: Global Liquid Biopsy Market, by Biomarker Type, Through 2023

Table 56: FDA-Approved or CE-Marked Tests with Epigenetic Component

Table 57: Global Liquid Biopsy Market, by Analysis Platform, Through 2023

Table 58: Global Liquid Biopsy Market, by Analysis Purpose, Through 2023

Table 59: Global Liquid Biopsy Market, by Region, Through 2023

Table 60: Limitations of Solid Biopsy in Cancer Applications

Table 61: Low-Frequency Mutation Detection

Table 62: Global Liquid Biopsy Cancer Market, by Indication, Through 2023

Table 63: Five-Year Survival Rate for Ovarian Cancer

Table 64: National Institutes of Health Liquid Biopsy Early Detection Initiative

Table 65: Molecular Thyroid Nodule Classifier Test Company Positioning

Table 66: Global Liquid Biopsy Cancer Market, by Analysis Purpose, Through 2023

Table 67: MRI and Liquid Biopsy Methods

Table 68: Early Detection Tissue of Origin Approaches

Table 69: Global Liquid Biopsy Cancer Market, by Biomarker Class, Through 2023

Table 70: Global Liquid Biopsy Cancer Market, by Analysis Method, Through 2023

Table 71: Global Breast Cancer Liquid Biopsy Market, by Analysis Method, Through 2023

- Table 72: Global Colorectal Cancer Liquid Biopsy Market, by Analysis Method, Through 2023
- Table 73: Global Hematological Cancer Market, by Analysis Method, Through 2023
- Table 74: Global Lung Cancer Liquid Biopsy Market, by Analysis Method, Through 2023
- Table 75: Global Pan-Cancer Liquid Biopsy Market, by Analysis Method, Through 2023
- Table 76: Global Cancer Liquid Biopsy Market, by Region, Through 2023
- Table 77: Global Liquid Biopsy Transplant Market, by Analysis Purpose, Through 2023
- Table 78: Global Liquid Biopsy Transplant Market, by Organ Type, Through 2023
- Table 79: Transplant Procedures Performed in the U.S., 2016-Sept. 30, 2018
- Table 80: Global Liquid Biopsy Transplant Market, by Analysis Method, Through 2023
- Table 81: Global Liquid Biopsy Transplant Market, by Biomarker Class, Through 2023
- Table 82: Global Transplant Liquid Biopsy Market, by Region, Through 2023
- Table 83: NIPT Test Prices Across the Globe, 2017
- Table 84: Global NIPT Market, by Analysis Purpose, Through 2023
- Table 85: Global NIPT Market, by Risk Type, Through 2023
- Table 86: Global NIPT Market, by Biomarker Class, Through 2023
- Table 87: Global NIPT Market, by Analysis Method, Through 2023
- Table 88: NGS NIPT Industry
- Table 89: Number of Tests and Market for NIPT, by Region and Company, 2015
- Table 90: Germany NGS-Based Noninvasive Prenatal Diagnostic Companies
- Table 91: Global NIPT Market, by Method, Through 2023
- Table 92: NIPTs Offered by Various Companies
- Table 93: Positive Predictive Values for High- and Average-Risk Cohorts
- Table 94: Comparison with Other NIPTs That are Based on Counting Technologies
- Table 95: Global Iona Test Market, by Country/Region, 2016 and 2017
- Table 96: informaseq Tests
- Table 97: informaseq Test Performance in the Most Common Chromosomal Aneuploidies
- Table 98: informaseq Test Performance in the Most Common Sex Chromosomes
- Table 99: VisibiliT Test Performance
- Table 100: Global NIPT Market, by Region, Through 2023
- Table 101: North American NIPT Market, by Country, Through 2023
- Table 102: Commercial Landscape of Noninvasive Prenatal Testing for Fetal Aneuploidy in the U.S.
- Table 103: U.S. Patents and Applications for Institutions Commercializing Noninvasive Prenatal Tests, 2012
- Table 104: European NIPT Market, by Country, Through 2023
- Table 105: Asia-Pacific NIPT Market, by Country, Through 2023
- Table 106: NIPT Technology Transfers, by Country

- Table 107: Patent Review of NIPT, by Year, 2010-2018
- Table 108: CTC-Related Patents, by Region, 2007-2019*
- Table 109: Cell-Free DNA-Related Patents, by Region, 2007-2017
- Table 110: Status of Liquid Biopsy- and Sequencing-Related Patent Disputes
- Table 111: Mergers and Acquisitions of Key Players, 2016-2018
- Table 112: New Products Launched by Key Players of NGS-NIPT Industry, 2017 and 2018
- Table 113: Agreements, Collaborations and Partnerships among Liquid Biopsy-NIPT Key Players, 2017 and 2018
- Table 114: Pipeline Analysis of Liquid Biopsy Industry, 2017 and 2018
- Table 115: 10x Genomics: Products and Services
- Table 116: Agilent Technologies: Financials, 2016-2017
- Table 117: Agilent Technologies: Products and Services
- Table 118: Berry Genomics: Products and Services
- Table 119: BGI: Products and Services
- Table 120: LifeCodexx: Products and Services
- Table 121: Illumina: Financials, 2016-2017
- Table 122: Illumina: Products and Services
- Table 123: LabCorp: Financials, 2016-2017
- Table 124: LabCorp: Products and Services
- Table 125: Natera: Financials, 2016-2017
- Table 126: Natera: Products and Services
- Table 127: Oxford Nanopore Technologies: Products and Services
- Table 128: Pacific Biosciences: Financials, 2016-2017
- Table 129: PacBio: Products and Services
- Table 130: PDx: Products and Services
- Table 131: QIAGEN: Financials, 2016-2017
- Table 132: QIAGEN: Products and Services
- Table 133: Roche Diagnostics: Division Sales, 2016-2017
- Table 134: Roche Diagnostics: Products and Services
- Table 135: Thermo Fisher: Financials, 2016-2017
- Table 136: Thermo Fisher: Products and Services

List Of Figures

LIST OF FIGURES

Summary Figure: Global Liquid Biopsy Market, by Disease Class, 2017-2023

Figure 1: Timeline of Liquid Biopsy Development

Figure 2: Molecular Applications of Biomarkers as Liquid Biopsy for Personalized Medicine

Figure 3: How Cancer Genomics Drives Liquid Biopsy

Figure 4: Clinical Applications of Liquid Biopsy for Precision Medicine

Figure 5: NIPT Using Massively Parallel Sequencing (MPS)

Figure 6: Global NIPT Market, by Risk Type, 2017-2023

Figure 7: Clinical Performance of NIFTY Test

Figure 8: Clinical Performance of Harmony Test

Figure 9: Clinical Performance of Panorama Test

Figure 10: North American NIPT Market, 2017-2023

Figure 11: European NIPT Market, 2017-2023

Figure 12: European NIPT Market Share, 2017

Figure 13: Mean Maternal Age in Five EU Countries, 2016

Figure 14: Total Number of Pregnancies and NIPT Procedures in Five EU Countries, 2016

Figure 15: Asia-Pacific NIPT Market, 2017-2023

Figure 16: RoW NIPT Market, 2017-2023

Figure 17: Prevalence of Down Syndrome by Mother's Age

Figure 18: Global NIPT Market Share, by Key Players, 2018

Figure 19: Thermo Fisher Scientific: Market Share, by Business Segments, 2018 (Q1)

I would like to order

Product name: Liquid Biopsy with Emphasis on NIPT: Global Markets to 2023

Product link: <https://marketpublishers.com/r/LC0C996EC47EN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LC0C996EC47EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970